Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1994 Nov;57(Suppl):72–75. doi: 10.1136/jnnp.57.suppl.72

Immunoglobulin treatment in human and experimental epilepsy.

B G van Engelen 1, W O Renier 1, C M Weemaes 1
PMCID: PMC1016733  PMID: 7964861

Abstract

The relationship between human immunoglobulin administration, and human and experimental epilepsy was investigated by reviewing the literature as well as the authors' clinical and experimental studies. The focus was: 1) the possible efficacy of IVIg; 2) the possibility that IVIg significantly increases CSF IgG and could reach the brain, and 3) the interaction between the IVIg preparation and epilepsy. There is still no formal proof of efficacy of IVIg treatment in epilepsy. However, the clinical data presented suggests that IVIg is likely to be effective in a subgroup of patients with intractable and epilepsy, and may be considered as a safe add-on medication in various types of idiopathic and symptomatic intractable epilepsy. From the authors' study on cerebrospinal fluid IgG concentrations before and after IVIg treatment in patients with epilepsy, it is concluded that the main component of the IVIg preparation (the IgG molecule) crosses the blood-CSF barrier, significantly increases CSF IgG concentration, and may reach the brain and act centrally. From a review of previous reports and two immunological studies carried out by the authors it is concluded that immunogenetic mechanisms may play a role in triggering or maintaining some types of epilepsy. In view of this, IVIg could act on epilepsy by its broad immunomodulatory mechanism of action. In addition, preliminary data are reported that contribute to the hypothesis that IVIg may have a direct neuromodulating effect.

Full text

PDF
72

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Duse M., Tiberti S., Plebani A., Avanzini M. A., Gardenghi M., Menegati E., Monafo V., Ugazio A. G. IgG2 deficiency and intractable epilepsy of childhood. Monogr Allergy. 1986;20:128–134. [PubMed] [Google Scholar]
  2. Dwyer J. M. Manipulating the immune system with immune globulin. N Engl J Med. 1992 Jan 9;326(2):107–116. doi: 10.1056/NEJM199201093260206. [DOI] [PubMed] [Google Scholar]
  3. Eeg-Olofsson O., Osterland C. K., Guttmann R. D., Andermann F., Prchal J. F., Andermann E., Janjua N. A. Immunological studies in focal epilepsy. Acta Neurol Scand. 1988 Nov;78(5):358–368. doi: 10.1111/j.1600-0404.1988.tb03671.x. [DOI] [PubMed] [Google Scholar]
  4. Fontana A., Grob P. J., Sauter R., Joller H. IgA deficiency, epilepsy, and hydantoin medication. Lancet. 1976 Jul 31;2(7979):228–231. doi: 10.1016/s0140-6736(76)91028-x. [DOI] [PubMed] [Google Scholar]
  5. Graff G., Lancet M. [Is it possible to influence the sex of the fetus during fertilization?]. Harefuah. 1972 Mar 1;82(5):228–229. [PubMed] [Google Scholar]
  6. Haraldsson A., van Engelen B. G., Renier W. O., Bakkeren J. A., Weemaes C. M. Light chain ratios and concentrations of serum immunoglobulins in children with epilepsy. Epilepsy Res. 1992 Dec;13(3):255–260. doi: 10.1016/0920-1211(92)90060-7. [DOI] [PubMed] [Google Scholar]
  7. Hrachovy R. A., Frost J. D., Jr Infantile spasms. Pediatr Clin North Am. 1989 Apr;36(2):311–329. doi: 10.1016/s0031-3955(16)36651-2. [DOI] [PubMed] [Google Scholar]
  8. Hrachovy R. A., Frost J. D., Jr, Pollack M. S., Glaze D. G. Serologic HLA typing in infantile spasms. Epilepsia. 1988 Nov-Dec;29(6):817–819. doi: 10.1111/j.1528-1157.1988.tb04239.x. [DOI] [PubMed] [Google Scholar]
  9. Lombroso C. T. A prospective study of infantile spasms: clinical and therapeutic correlations. Epilepsia. 1983 Apr;24(2):135–158. doi: 10.1111/j.1528-1157.1983.tb04874.x. [DOI] [PubMed] [Google Scholar]
  10. Minev M., Martinova F., Belopitova L. On the association of the HLA system with epilepsy in children. Epilepsia. 1987 Jan-Feb;28(1):74–76. doi: 10.1111/j.1528-1157.1987.tb03626.x. [DOI] [PubMed] [Google Scholar]
  11. Montelli T. C., Mota N. G., Peraçoli M. T., Torres E. A., Rezkallah-Iwasso M. T. Immunological disturbance in West and Lennox-Gastaut syndromes. Arq Neuropsiquiatr. 1984 Jun;42(2):132–139. doi: 10.1590/s0004-282x1984000200005. [DOI] [PubMed] [Google Scholar]
  12. Mota N. G., Rezkallah-Iwasso M. T., Peraçoli M. T., Montelli T. C. Demonstration of antibody and cellular immune response to brain extract in West and Lennox-Gastaut syndromes. Arq Neuropsiquiatr. 1984 Jun;42(2):126–131. doi: 10.1590/s0004-282x1984000200004. [DOI] [PubMed] [Google Scholar]
  13. Pacifici R., Paris L., Di Carlo S., Pichini S., Zuccaro P. Immunologic aspects of carbamazepine treatment in epileptic patients. Epilepsia. 1991 Jan-Feb;32(1):122–127. doi: 10.1111/j.1528-1157.1991.tb05622.x. [DOI] [PubMed] [Google Scholar]
  14. Peress N. S., Siegelman J., Fleit H. B. High avidity periventricular IgG-Fc receptor activity in human and rabbit brain. Clin Immunol Immunopathol. 1987 Feb;42(2):229–238. doi: 10.1016/0090-1229(87)90010-9. [DOI] [PubMed] [Google Scholar]
  15. Plioplys A. V., Greaves A., Yoshida W. Anti-CNS antibodies in childhood neurologic diseases. Neuropediatrics. 1989 May;20(2):93–102. doi: 10.1055/s-2008-1071273. [DOI] [PubMed] [Google Scholar]
  16. Péchadre J. C., Sauvezie B., Osier C., Gibert J. Traitement des encéphalopathies épileptiques de l'enfant par les gamma-globulines. Rev Electroencephalogr Neurophysiol Clin. 1977 Oct-Dec;7(4):443–447. doi: 10.1016/s0370-4475(77)80049-x. [DOI] [PubMed] [Google Scholar]
  17. Reichlin S. Neuroendocrine-immune interactions. N Engl J Med. 1993 Oct 21;329(17):1246–1253. doi: 10.1056/NEJM199310213291708. [DOI] [PubMed] [Google Scholar]
  18. Smeraldi E., Scorza Smeraldi R., Cazzullo C. L., Guareschi Cazzullo A., Fabio G., Canger R. Immunogenetics of the Lennox-Gastaut syndrome: frequency of HL-A antigens and haplotypes in patients and first-degree relatives. Epilepsia. 1975 Dec;16(5):699–703. doi: 10.1111/j.1528-1157.1975.tb04754.x. [DOI] [PubMed] [Google Scholar]
  19. Smeraldi E., Scorza Smeraldi R., Cazzullo C. L., Guareschi Cazzullo A., Fabio G., Canger R. Immunogenetics of the Lennox-Gastaut syndrome: frequency of HL-A antigens and haplotypes in patients and first-degree relatives. Epilepsia. 1975 Dec;16(5):699–703. doi: 10.1111/j.1528-1157.1975.tb04754.x. [DOI] [PubMed] [Google Scholar]
  20. Voskuyl R. A., Dingemanse J., Danhof M. Determination of the threshold for convulsions by direct cortical stimulation. Epilepsy Res. 1989 Mar-Apr;3(2):120–129. doi: 10.1016/0920-1211(89)90039-9. [DOI] [PubMed] [Google Scholar]
  21. van Engelen B. G., Renier W. O., Weemaes C. M., Lamers K. J., Gabreels F. J., Meinardi H. Cerebrospinal fluid examinations in cryptogenic West and Lennox-Gastaut syndrome before and after intravenous immunoglobulin administration. Epilepsy Res. 1994 Jun;18(2):139–147. doi: 10.1016/0920-1211(94)90006-x. [DOI] [PubMed] [Google Scholar]
  22. van Engelen B. G., de Waal L. P., Weemaes C. M., Renier W. O. Serologic HLA typing in cryptogenic Lennox-Gastaut syndrome. Epilepsy Res. 1994 Jan;17(1):43–47. doi: 10.1016/0920-1211(94)90078-7. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES